Home

Explore NIH Technologies

Explore work by over 1,500 NIH researchers   |   Available for Licensing & Collaboration

 
Ellipsoid zone (EZ) loss has been proposed as evidence of progression of several retinal degenerative diseases, including, but not limited to, retinitis pigmentosa and hydroxychloroquine (HCQ)-induced retinal toxicity. HCQ is a first-line drug used to treat autoimmune diseases such as systemic lupus
Glaucoma is one of the world’s leading causes of irreversible blindness, and currently, no therapies exist to directly protect retinal ganglion cells (RGC) from degradation and loss. NIH inventors have developed a method to treat glaucoma using exosomes derived from bone marrow-derived mesenchymal
1 in every 200 people with eye-related irritation in the US has uveitis. Vision loss can occur if the uveitis remains untreated, therefore, early detection is crucial. Certain uveitis cases currently require fluorescein angiography (FA) for diagnosis due to its ability to display retinal vascular

Explore Featured Research

Get updates on the latest and most exciting research coming out of NIH...

Read More >

Explore Featured Products

Novel and interesting products coming to market through NIH inventions and partnerships...

Read More >